Anzeige
Mehr »
Lynx Broker
Login
Mittwoch, 16.10.2019 Börsentäglich über 12.000 News von 613 internationalen Medien
Konkurrenz beeindruckt! Bisher noch unentdeckt von Investoren ist die neue Technologie jetzt marktreif! Aktie vor Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H5GS ISIN: SE0010323311 Ticker-Symbol: B9A 
Frankfurt
16.10.19
08:03 Uhr
5,910 Euro
-0,025
-0,42 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOARCTIC AB Chart 1 Jahr
5-Tage-Chart
BIOARCTIC AB 5-Tage-Chart

Aktuelle News zur BIOARCTIC Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:36Invitation to presentation of BioArctic's Interim Report for the period January - September 2019 on October 24 at 9.30 a.m. CET-
18.07.BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 201986STOCKHOLM, July 18, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The presentations were held by...
► Artikel lesen
15.07.BioArctic's Co-Founder Received AAIC Lifetime Achievement Award33Professor Lars Lannfelt received prestigious international award for outstanding research in Alzheimer's disease STOCKHOLM, July 15, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq...
► Artikel lesen
BIOARCTIC Aktien jetzt im kostenlosen Demokonto handeln!
11.07.BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 201974STOCKHOLM, July 11, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the Alzheimer's Association...
► Artikel lesen
23.05.BioArctic Strengthens its Blood-brain Barrier Technology Platform With World Leading Scientist Recruitment33STOCKHOLM, May 23, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. Per-Ola Freskgård...
► Artikel lesen
20.05.BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease36STOCKHOLM, May 20, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai...
► Artikel lesen
10.05.BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease34STOCKHOLM, May 10, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer's Clinical Trials Consortium (ACTC) and BioArctic's partner Eisai...
► Artikel lesen
09.05.XFRA DIVIDEND/INTEREST INFORMATION - 10.05.2019 - 368FOLGENDE WERTPAPIERE WERDEN AM 09.05.2019 CUM DIVIDENDE/ZINSEN UND AM 10.05.2019 EX DIVIDENDE/ZINSEN GEHANDELT. THE PRE-DIVIDEND/INTEREST DAY OF THE FOLLOWING SHARES WILL BE 09.05.2019. THE EX-DIVIDEND/INTEREST...
► Artikel lesen
03.04.BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies27STOCKHOLM, April 3, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a non-diluting grant of MSEK 5 from Sweden's Innovation...
► Artikel lesen
22.03.XFRA B9A: WIEDERAUFNAHME/RESUMPTION27FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT...
► Artikel lesen
22.03.Nasdaq Stockholm AB: Lift of Suspension in BioArctic AB at XSTO (39/19)33Lifting of Suspension At Trading Venue XSTO Issuer: BioArctic AB, LEI: 549300Y0OI2WVUNHLC33 -------------------------------------------------------------------------------- Instrument:...
► Artikel lesen
22.03.BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease54STOCKHOLM, Sweden, March 21, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study...
► Artikel lesen
21.03.XFRA B9A: AUSSETZUNG/SUSPENSION24DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL BIOARCTIC AB...
► Artikel lesen
14.03.BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease44STOCKHOLM, March 13, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible...
► Artikel lesen
07.03.BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease38STOCKHOLM, March 7, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with...
► Artikel lesen
14.02.BioArctic - Full Year Report January - December 201825STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson portfolio October...
► Artikel lesen
13.02.BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 233STOCKHOLM, Feb. 13, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase 1/2 study now has been treated...
► Artikel lesen
11.02.BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-080536ABBV-0805 is being evaluated as a potential disease modifying treatment for Parkinson's Disease STOCKHOLM, Feb. 11, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B)...
► Artikel lesen
04.02.BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease38STOCKHOLM, Feb. 4, 2019 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that Eisai stated at their Q3 FY2018 Financial Results Meeting on February 4, 2019 that...
► Artikel lesen
14.12.18BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance64STOCKHOLM, Dec. 14, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1